35672148|t|Microglial mTOR Activation Upregulates Trem2 and Enhances beta-Amyloid Plaque Clearance in the 5XFAD Alzheimer's Disease Model.
35672148|a|The mechanistic target of rapamycin (mTOR) signaling pathway plays a major role in key cellular processes including metabolism and differentiation; however, the role of mTOR in microglia and its importance in Alzheimer's disease (AD) have remained largely uncharacterized. We report that selective loss of Tsc1, a negative regulator of mTOR, in microglia in mice of both sexes, caused mTOR activation and upregulation of Trem2 with enhanced beta-Amyloid (Abeta) clearance, reduced spine loss, and improved cognitive function in the 5XFAD AD mouse model. Combined loss of Tsc1 and Trem2 in microglia led to reduced Abeta clearance and increased Abeta plaque burden revealing that Trem2 functions downstream of mTOR. Tsc1 mutant microglia showed increased phagocytosis with upregulation of CD68 and Lamp1 lysosomal proteins. In vitro studies using Tsc1-deficient microglia revealed enhanced endocytosis of the lysosomal tracker indicator Green DND-26 suggesting increased lysosomal activity. Incubation of Tsc1-deficient microglia with fluorescent-labeled Abeta revealed enhanced Abeta uptake and clearance, which was blunted by rapamycin, an mTOR inhibitor. In vivo treatment of mice of relevant genotypes in the 5XFAD background with rapamycin, affected microglial activity, decreased Trem2 expression and reduced Abeta clearance causing an increase in Abeta plaque burden. Prolonged treatment with rapamycin caused even further reduction of mTOR activity, reduction in Trem2 expression, and increase in Abeta levels. Together, our findings reveal that mTOR signaling in microglia is critically linked to Trem2 regulation and lysosomal biogenesis, and that the upregulation of Trem2 in microglia through mTOR activation could be exploited toward better therapeutic avenues to Abeta-related AD pathologies.SIGNIFICANCE STATEMENT Mechanistic target of rapamycin (mTOR) signaling pathway is a key regulator for major cellular metabolic processes. However, the link between mTOR signaling and Alzheimer's disease (AD) is not well understood. In this study, we provide compelling in vivo evidence that mTOR activation in microglia would benefit beta-Amyloid (Abeta)-related AD pathologies, as it upregulates Trem2, a key receptor for Abeta plaque uptake. Inhibition of mTOR pathway with rapamycin, a well-established immunosuppressant, downregulated Trem2 in microglia and reduced Abeta plaque clearance indicating that mTOR inactivation may be detrimental in Abeta-associated AD patients. This finding will have a significant public health impact and benefit, regarding the usage of rapamycin in AD patients, which we believe will aggravate the Abeta-related AD pathologies.
35672148	11	15	mTOR	Gene	56717
35672148	39	44	Trem2	Gene	83433
35672148	101	120	Alzheimer's Disease	Disease	MESH:D000544
35672148	132	163	mechanistic target of rapamycin	Gene	56717
35672148	165	169	mTOR	Gene	56717
35672148	297	301	mTOR	Gene	56717
35672148	337	356	Alzheimer's disease	Disease	MESH:D000544
35672148	358	360	AD	Disease	MESH:D000544
35672148	434	438	Tsc1	Gene	64930
35672148	464	468	mTOR	Gene	56717
35672148	486	490	mice	Species	10090
35672148	513	517	mTOR	Gene	56717
35672148	549	554	Trem2	Gene	83433
35672148	583	588	Abeta	Gene	11820
35672148	666	668	AD	Disease	MESH:D000544
35672148	669	674	mouse	Species	10090
35672148	699	703	Tsc1	Gene	64930
35672148	708	713	Trem2	Gene	83433
35672148	742	747	Abeta	Gene	11820
35672148	772	777	Abeta	Gene	11820
35672148	807	812	Trem2	Gene	83433
35672148	837	841	mTOR	Gene	56717
35672148	843	847	Tsc1	Gene	64930
35672148	916	920	CD68	Gene	12514
35672148	925	930	Lamp1	Gene	16783
35672148	974	978	Tsc1	Gene	64930
35672148	1070	1076	DND-26	Chemical	-
35672148	1132	1136	Tsc1	Gene	64930
35672148	1182	1187	Abeta	Gene	11820
35672148	1206	1211	Abeta	Gene	11820
35672148	1255	1264	rapamycin	Chemical	MESH:D020123
35672148	1269	1273	mTOR	Gene	56717
35672148	1306	1310	mice	Species	10090
35672148	1362	1371	rapamycin	Chemical	MESH:D020123
35672148	1413	1418	Trem2	Gene	83433
35672148	1442	1447	Abeta	Gene	11820
35672148	1481	1486	Abeta	Gene	11820
35672148	1527	1536	rapamycin	Chemical	MESH:D020123
35672148	1570	1574	mTOR	Gene	56717
35672148	1598	1603	Trem2	Gene	83433
35672148	1632	1637	Abeta	Gene	11820
35672148	1681	1685	mTOR	Gene	56717
35672148	1733	1738	Trem2	Gene	83433
35672148	1805	1810	Trem2	Gene	83433
35672148	1832	1836	mTOR	Gene	56717
35672148	1904	1909	Abeta	Gene	11820
35672148	1918	1920	AD	Disease	MESH:D000544
35672148	1956	1987	Mechanistic target of rapamycin	Gene	56717
35672148	1989	1993	mTOR	Gene	56717
35672148	2098	2102	mTOR	Gene	56717
35672148	2117	2136	Alzheimer's disease	Disease	MESH:D000544
35672148	2138	2140	AD	Disease	MESH:D000544
35672148	2225	2229	mTOR	Gene	56717
35672148	2282	2287	Abeta	Gene	11820
35672148	2297	2299	AD	Disease	MESH:D000544
35672148	2331	2336	Trem2	Gene	83433
35672148	2357	2362	Abeta	Gene	11820
35672148	2392	2396	mTOR	Gene	56717
35672148	2410	2419	rapamycin	Chemical	MESH:D020123
35672148	2473	2478	Trem2	Gene	83433
35672148	2504	2509	Abeta	Gene	11820
35672148	2543	2547	mTOR	Gene	56717
35672148	2583	2588	Abeta	Gene	11820
35672148	2600	2602	AD	Disease	MESH:D000544
35672148	2603	2611	patients	Species	9606
35672148	2707	2716	rapamycin	Chemical	MESH:D020123
35672148	2720	2722	AD	Disease	MESH:D000544
35672148	2723	2731	patients	Species	9606
35672148	2769	2774	Abeta	Gene	11820
35672148	2783	2785	AD	Disease	MESH:D000544
35672148	Negative_Correlation	11820	83433
35672148	Negative_Correlation	56717	64930
35672148	Positive_Correlation	56717	83433
35672148	Association	MESH:D000544	83433
35672148	Negative_Correlation	MESH:D020123	11820
35672148	Negative_Correlation	MESH:D020123	83433
35672148	Negative_Correlation	11820	64930
35672148	Association	11820	56717
35672148	Association	MESH:D000544	11820
35672148	Association	64930	83433
35672148	Positive_Correlation	12514	64930
35672148	Negative_Correlation	MESH:D020123	56717
35672148	Association	MESH:D000544	56717
35672148	Positive_Correlation	16783	64930

